Roche Reports Weight Loss and Lower Blood Sugar With an Experimental Diabetes Injection
Updated 23 September 2026
What Is Happening
Roche says its experimental weekly injection, enicepatide, reduced blood sugar and body weight in a study of 447 adults with type 2 diabetes and overweight or obesity. The medicine, also called CT-388, is still being tested and is not an approved treatment. This was a phase 2 trial: a mid-stage study used to assess doses, benefits and side effects before larger trials.
After 48 weeks, participants receiving the highest 24 mg dose had lost an average of 15.5% of their weight, according to Roche. Their HbA1c, a measure of average blood sugar over several months, fell by 2.65 percentage points from a starting level of 8.1%. Roche reported mainly mild-to-moderate digestive side effects; 2% of participants taking the drug stopped because of side effects, compared with none receiving placebo.
Enicepatide targets the same two hormone pathways as tirzepatide, the medicine in Eli Lilly’s Mounjaro and Zepbound. Fierce Biotech reported the results but cautioned against comparing separate trials. This study compared enicepatide with placebo, not Lilly’s drug, so it does not show that Roche’s treatment works better. Roche plans further late-stage diabetes trials.
Sources (2)
Companies Involved
Roche
Roche is a healthcare company headquartered in Basel, Switzerland, with businesses in pharmaceuticals and diagnostics.
Mentioned In
GLP-1 Market Monitor
Active companies
